title: Cilostazol and outcome in outpatients with peripheral artery disease.
abstract: BACKGROUND
  Cilostazol increases the walking distance in patients with intermittent claudication, but there is scarce evidence of any effect on the risk for subsequent ischemic events, bleeding or death.
  
  
  METHODS
  We used data from the FRENA Registry to compare the clinical outcome in stable outpatients with intermittent claudication, according to the use of cilostazol.
  
  
  RESULTS
  As of January 2013, 1,317 patients with intermittent claudication were recruited in FRENA, of whom 191 (14.5%) received cilostazol. Over a mean follow-up of 18months, 39 patients developed myocardial infarction, 23 ischemic stroke, 20 underwent limb amputation, 15 had major bleeding and 70 died. There were no significant differences in the rate of subsequent ischemic events, major bleeding or death between patients receiving or not receiving cilostazol. On multivariate analysis, the use of cilostazol had no influence on the risk for subsequent myocardial infarction (hazard ratio [HR]: 0.97; 95% CI: 0.33-20.8), ischemic stroke (HR: 1.46; 95% CI: 0.48-4.43), limb amputation (HR: 0.34; 95% CI: 0.04-20.6), major bleeding (HR: 1.52; 95% CI: 0.33-7.09) or death (HR: 0.90; 95% CI: 0.40-20.0).
  
  
  CONCLUSIONS
  In stable outpatients with intermittent claudication, the use of cilostazol was not associated with increased rates of subsequent ischemic events, major bleeding or death.
authors.affiliation: Department of Vascular Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Facultad de Medicina, Universitat Autónoma de Barcelona, Spain.
authors.forename: Paulina
authors.initials: P
authors.lastname: Perez
authors.affiliation: Department of Vascular Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Esteban
authors.affiliation: Department of Internal Medicine, Hospital Municipal de Badalona, Badalona, Spain.
authors.forename: Joan Carles
authors.initials: JC
authors.lastname: Sauquillo
authors.affiliation: Department of Angiology and Vascular Surgery, Hospital de Terrassa, Terrassa, Barcelona, Spain.
authors.forename: Monserrat
authors.initials: M
authors.lastname: Yeste
authors.affiliation: Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Manzano
authors.affiliation: Department of Internal Medicine, Hospital Universitari Parc Taulí Sabadell, Sabadell, Spain.
authors.forename: Abel
authors.initials: A
authors.lastname: Mujal
authors.affiliation: Department of Neurology, Hospital San Pedro de Alcántara, Cáceres, Spain.
authors.forename: Pedro Enrique
authors.initials: PE
authors.lastname: Jiménez Caballero
authors.affiliation: Department of Internal Medicine, Hospital de Alcañiz, Alcañiz, Teruel, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Aguilar
authors.affiliation: Department of Internal Medicine, Hospital San Pedro de Alcántara, Cáceres, Spain.
authors.forename: Juan Francisco
authors.initials: JF
authors.lastname: Sánchez Muñoz-Torrero
authors.affiliation: Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. Electronic address: mmonreal.germanstrias@gencat.cat.
authors.forename: Manuel
authors.initials: M
authors.lastname: Monreal
mesh_terms: D000368:Aged; D000077407:Cilostazol; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced; D010045:Outpatients; D058729:Peripheral Arterial Disease / Q000188:drug therapy*; D058987:Phosphodiesterase 3 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012042:Registries; D020521:Stroke / Q000139:chemically induced; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D058987:Phosphodiesterase 3 Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol
keywords: Cilostazol; Intermittent claudication; Outcome; Safety